<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01557478</url>
  </required_header>
  <id_info>
    <org_study_id>MIQOL-B</org_study_id>
    <nct_id>NCT01557478</nct_id>
  </id_info>
  <brief_title>Melatonin as Adjuvant Therapy in Breast Cancer Patients</brief_title>
  <acronym>MIQOL-B</acronym>
  <official_title>Melatonin in Improving the Quality of Life of Breast Cancer Patients and Reduction of Postoperative Pain and Chemotherapy Induced Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Council of Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Srinagarind Hospital, Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maharat Hospital, Nakhon Ratchasima</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Drug House Ltd., Bangkok</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluate the effect of melatonin in improving quality of life and reducing post
      operative pain and chemotherapy-induced toxicity in breast cancer patients. This is a
      multi-center, randomized, double-blind, placebo controlled trial conducted in stage II or III
      breast cancer patients. Mixed-block randomization, stratified by center and treatment scheme
      is used to divide eligible patients into two groups: melatonin 20 mg or matched placebo. The
      patients are required to take the studied drugs at night (after 21.00 pm) on the first night
      prior to surgery and continue for 24 months. Standard treatment is surgery followed by
      chemotherapy according to each center's standard protocol. Study endpoints are QOL (FACT-B),
      pain (VAS 0-10), adverse event frequency, sleep quality (VAS 0-10), recurrence rate and
      progression-free survival.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life (FACT-B Version 4)</measure>
    <time_frame>Change from baseline in TOI scores at 6 months</time_frame>
    <description>Self-reported questionnaire. FACT-B Thai Version 4 has been previously validated. Change from baseline will be evaluated at months 2,4,6,12,18,24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain and amount of pain medication used</measure>
    <time_frame>Before and up to 72 hours after surgery.</time_frame>
    <description>Self-reported VAS scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline and months 2,3,4,5,6,12,18,24</time_frame>
    <description>CTCAE Version 4.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Baseline, up to 72 hours after surgery and months 2,3,4,5,6,12,18,24</time_frame>
    <description>Self reported VAS scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer recurrence incidence</measure>
    <time_frame>participant will be followed for the duration of study, an expected average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>participant will be followed for the duration of study, an expected average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Stage II and III Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo (identical formulation and delivery, without active ingredient)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg melatonin gelatin capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study</description>
    <arm_group_label>Melatonin 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>match placebo</intervention_name>
    <description>placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study</description>
    <arm_group_label>Matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven stage II or III breast cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

          -  platelet count ≥100,000 cells/mm3

          -  white blood cell count ≥ 3,000 cell/mm3

          -  hemoglobin ≥ 10 g/dL

          -  serum creatinine ≤ 1.5 mg/dL

          -  bilirubin ≤ 2 mg/dL

          -  AST ≤ 2.5 times upper limit of normal (ULN)

          -  New York Heart Association grade ≤ 2

          -  written consent

        Exclusion Criteria:

          -  received prior chemotherapy or biotherapy, radiotherapy or surgery within 1 month
             preceding randomization,

          -  had more than one type of cancer or brain metastasis

          -  moderate neuropathy (CTCAE grade ≥ 2)

          -  active infection

          -  uncontrolled complications (i.e. blood glucose &gt; 200 mg/dL, uncontrolled hypertension,
             unstable angina, history of congestive heart failure or history of myocardial
             infarction within one year).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nutjaree P Johns, PharmD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharat Nakorn Ratchasima Hospital</name>
      <address>
        <city>Nakorn Ratchasima</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2012</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Nutjaree Pratheepawanit Johns</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>melatonin</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>pain</keyword>
  <keyword>sleep</keyword>
  <keyword>survival</keyword>
  <keyword>adverse events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

